section name header

Pronunciation ⬇

REV-e-fen-a-sin

Classifications ⬆ ⬇

Therapeutic Classification: bronchodilators

Pharmacologic Classification: anticholinergics

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Acts as an anticholinergic by inhibiting the M3 receptor in bronchial smooth muscle, which leads to bronchodilation.
Therapeutic effects:
  • Bronchodilation with lessened symptoms of COPD.

Pharmacokinetics ⬆ ⬇

Absorption: 3% systemically absorbed following oral inhalation.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Rapidly hydrolyzed to an active metabolite. Primarily eliminated in feces (88%) with less than 5% excreted in urine.

Half-Life: 22–70 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
Nebulizationrapid14–41 min24 hr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Yupelri